Isolation and characterization of a novel Enterococcus faecalis bacteriophage φEF24C as a therapeutic candidate
Isolation and characterization of a novel Enterococcus faecalis bacteriophage φEF24C as a therapeutic candidate
复制标题
DOI：
10.1111/j.1574-6968.2007.00996.x
复制
发表时间：
2008-01-01
影响因子：
2.1
通讯作者：
Matsuzaki, Shigenobu
中科院分区：
文献类型：
--
作者：
Uchiyama, Jumpei;Rashel, Mohammad;Matsuzaki, Shigenobu
耐万古霉素粪肠球菌（VRE）已成为医院环境中的重大威胁。噬菌体（噬菌体）疗法经常被提议作为治疗该细菌引起的感染的潜在替代疗法。为寻找治疗粪肠球菌感染的候选药物，从环境中分离到30株粪肠球菌。其中之一，毒性噬菌体phi EF 24 C，它具有广泛的宿主范围，被选择用于分析。phi EF 24 C的噬斑形成能力几乎不受临床宿主菌株差异的影响。此外，噬菌体具有较短的潜伏期和较大的爆发大小比普通的尾噬菌体，表明phi EF 24 C具有有效的裂解活性，对许多粪肠球菌菌株，包括VRE。形态学和基因组分析表明，phi EF 24 C是一种大型肌病毒（分类为肌病毒科形态型A1），具有c. 143 kbp。病毒体蛋白的N-末端氨基酸序列的分析，连同形态和基因组大小，推测phi EF 24 C是密切相关的革兰氏阳性细菌的其他肌病毒，已被实验或实际用于治疗或预防。考虑到这些结果，phi EF 24 C可能是一个潜在的候选治疗性噬菌体对粪肠球菌感染。
Vancomycin-resistant Enterococcus faecalis (VRE) has become a significant threat in nosocomial settings. Bacteriophage (phage) therapy is frequently proposed as a potential alternative therapy for infections caused by this bacterium. To search for candidate therapeutic phages against Enterococcus faecalis infections, 30 Enterococcus faecalis phages were isolated from the environment. One of these, virulent phage phi EF24C, which has a broad host range, was selected for analysis. The plaque-forming ability of phi EF24C was virtually unaffected by differences in the clinical host strains. Furthermore, the phage had a shorter latent period and a larger burst size than ordinary tailed phages, indicating that phi EF24C has effective lytic activity against many Enterococcus faecalis strains, including VRE. Morphological and genomic analyses revealed that phi EF24C is a large myovirus (classified as family Myoviridae morphotype A1) with a linear double-stranded DNA genome of c. 143 kbp. Analyses of the N-terminal amino acid sequences of the virion proteins, together with the morphology and the genome size, speculated that phi EF24C is closely related to other myoviruses of Gram-positive bacteria that have been used experimentally or practically for therapy or prophylaxis. Considering these results, phi EF24C may be a potential candidate therapeutic phage against Enterococcus faecalis infections.